|Articles|September 15, 2003
European study's interim results favorable for myopic PRL
Author(s)Cheryl Guttman
San Francisco-An interim analysis of data from an ongoing European multicenter study of the Phakic Refractive Lens (PRL, CIBA Vision/Medennium) indicates that the posterior chamber implant is a safe, effective, and predictable method for correcting high myopia, said Bo Philipson, MD, PhD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Articles
- The European Commission grants marketing authorization for EYLUXVI
September 23rd 2025
- Luxa Biotechnology announces clinical trial results for treatment of AMD
September 22nd 2025
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Idebenone accepted by FDA for priority review for Leber Hereditary Optic Neuropathy
2
Luxa Biotechnology announces clinical trial results for treatment of AMD
3
The European Commission grants marketing authorization for EYLUXVI
4
FDA approves abbreviated new drug application from Amneal Pharmaceuticals for bimatoprost ophthalmic solution 0.01%
5